{'fraction_non_alphanumeric': 0.014941302027748132, 'fraction_numerical': 0.004268943436499467, 'mean_word_length': 5.559440559440559, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Molecular Profile of the BCL2 Family of the Apoptosis Related Genes in Breast Cancer Cells after Treatment with Cytotoxic/Cytostatic Drugs

BCL2 (bcl-2) gene family members are important regulators of apoptosis. Increasing evidence supports their modulated expression in breast cancer cells and in many cases their relation to chemotherapy response, outcome, and overall prognosis, as well as their value as important potent therapeutic targets. Investigation and increased understanding of their transcriptional regulation and their specific roles in cancer progression and therapy response will be useful for focusing research on the development of novel therapies targeted against this gene family members’ expression status. In the present review, we describe current knowledge of the molecular profile of the classical and novel members of the BCL2 family of genes as a response of breast cancer cells to cytotoxic/cytostatic drugs.